Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-01-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于海思科医药集团股份有限公司2024年度持续督导培训情况报告
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导培训情况报告" which translates to "Continuous Supervision Training Report". It is issued by Huatai United Securities Co., Ltd. as the sponsor institution for Hisun Pharmaceutical Group Co., Ltd. The content describes a training session conducted on December 27, 2024, for company directors, supervisors, senior management, controlling shareholders, and board office staff. The report summarizes the training content, participants, and effectiveness, focusing on regulatory compliance and fundraising usage norms. The document length is short (1228 characters) and it is a report on a specific training event related to regulatory supervision and sponsor duties, not a financial report, earnings release, or management discussion. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a meeting presentation or voting result. It is a specialized report on continuous supervision training by the sponsor institution, which is a regulatory compliance related report but does not fit the fallback Regulatory Filings (RNS) because it is a formal report on training activities. The closest fitting category is Regulatory Filings (RNS) as it is a regulatory compliance related report that does not fit other categories better.
2025-01-09 Chinese
华泰联合证券有限责任公司关于海思科医药集团股份有限公司2024年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "现场检查报告" (On-site Inspection Report) conducted by 华泰联合证券有限责任公司 (Huatai United Securities Co., Ltd.) regarding 海思科医药集团股份有限公司 (Haisco Pharmaceutical Group Co., Ltd.) for the year 2024. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines related to sponsorship and supervision of securities issuance. The content includes detailed checks on corporate governance, internal controls, information disclosure, use of raised funds, performance, and compliance with commitments. It is a detailed supervisory inspection report by the sponsor institution, not a full annual or interim financial report, nor an earnings release or audit report. It is a standalone audit-related supervisory document focusing on compliance and internal controls, consistent with an Audit Report / Information (AR) category. The document length is 4249 characters, which is sufficient to contain substantive content, not just an announcement or certification. Therefore, the best fitting category is AR (Audit Report / Information). FY 2024
2025-01-09 Chinese
关于2021年限制性股票激励计划第三个解除限售期解除限售股份上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the lifting of restrictions on shares under a 2021 restricted stock incentive plan. It includes information about board and supervisory meetings, legal opinions, approval procedures, and specifics about the number of shares becoming unrestricted and their listing date. The content focuses on share unlocking and listing related to an employee stock incentive plan, which is a capital structure change event. It is not a full financial report, earnings release, or management discussion. It is not a simple announcement of a report publication but a substantive disclosure about share capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to the clear focus on share unlocking and capital structure changes.
2025-01-09 Chinese
关于2025年第一次临时股东大会增加临时提案暨补充通知的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a detailed announcement regarding the convening of the company's 2025 first extraordinary general meeting of shareholders (临时股东大会). It includes information about the meeting date, voting procedures, proposals to be voted on, registration details, and proxy forms. The content focuses on the notification and procedural details for the shareholders' meeting rather than the results of the vote or the meeting itself. It is not a report of voting results, nor is it a proxy solicitation statement or a management report. The document is also not a full annual or interim report, earnings release, or any other financial report. Given the detailed nature of the meeting notice and the inclusion of agenda items and voting instructions, this fits the category of a shareholder meeting notice or announcement. Since the document is about the notice and supplementary information for the extraordinary general meeting, it best fits the category of "Declaration of Voting Results & Voting Rights Announcements (DVA)" or possibly "Proxy Solicitation & Information Statement (PSI)". However, the document does not solicit votes but announces the meeting and voting procedures. It is more aligned with a meeting notice and voting announcement. Given the options, the best fit is DVA, but since it does not contain voting results yet, it is more of a meeting notice and agenda announcement. The closest category is Regulatory Filings (RNS) as a fallback for miscellaneous regulatory announcements that do not fit other categories exactly. However, the document is a formal announcement of the meeting and agenda, which is typically classified as a Proxy Solicitation & Information Statement (PSI). But PSI usually includes solicitation materials, not just meeting notices. The document is a notice of the meeting and agenda, so the best classification is DVA (Declaration of Voting Results & Voting Rights Announcements) because it relates to voting rights and meeting agenda announcements. Confidence is high due to the detailed meeting and voting information provided.
2025-01-05 Chinese
第五届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 21st meeting of the 5th Board of Directors of 海思科医药集团股份有限公司. It details voting results on various corporate matters such as stock incentive plans, fundraising project completion, capital increases in subsidiaries, and proposals for shareholder meetings. The text includes phrases like '会议决议公告' (meeting resolution announcement) and references to board meeting procedures and votes. There is no detailed financial data, earnings information, or full report content. The document is not an annual or interim report, nor a call transcript or audit report. It is clearly an announcement of board/management decisions and changes, fitting the category of Board/Management Information (MANG). The document length is under 5,000 characters and it is a direct announcement, not a report publication notice or certification. Therefore, the correct classification is MANG with high confidence.
2025-01-05 Chinese
关于对控股公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a capital increase (增资) involving the company's controlling subsidiaries and related parties. It details the transaction structure, parties involved, investment amounts, and the strategic rationale behind the capital increase. The document is titled as an announcement (公告) and contains no financial statements or detailed financial performance data. It primarily focuses on the update of financing activities and related party transactions. The document length is 4195 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2025-01-05 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.